Melanotan-2
MT-II, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Melanotan-2 (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts as a non-selective melanocortin receptor agonist. Originally developed for skin pigmentation research, it has also been investigated for erectile dysfunction. NOT FDA approved and carries significant safety warnings from health agencies worldwide due to serious adverse effects including potential melanoma risk.
Complete Dosing Guide
Quick Reference
Administration Method
Subcutaneous injection (research protocols only)
Step-by-Step Dosing Protocol
Dosing Guidelines
Research protocols utilized subcutaneous doses of 0.01-0.03 mg/kg body weight. Optimal efficacy/tolerability observed at 0.025 mg/kg (approximately 1.5-2mg for 70kg individual). Phase I study escalated from 0.01 mg/kg with good tolerance. Higher doses (0.03 mg/kg) associated with Grade II somnolence and fatigue. CRITICAL WARNING: Case reports of severe toxicity at 6mg doses demonstrate narrow therapeutic window. Due to lack of approval and safety concerns, no standardized clinical dosing protocols exist. Research use only under medical supervision.
The research studies used very small amounts - about 1.5-2mg injections for an average-sized person. However, this is research-only dosing that is NOT approved for regular use. Even these small research doses caused significant side effects in many people. Some individuals have seriously harmed themselves by using much higher doses than what was studied. Since this peptide is not approved, there are no safe dosing guidelines for the public.
Mixing & Injection
Clinical studies utilized subcutaneous injection, typically in the abdomen or thigh. Injection timing was generally in the morning to align with natural circadian melanocortin rhythms. Lyophilized powder requires reconstitution with bacteriostatic water. Injection sites should be rotated to prevent tissue damage. Research protocols included monitoring for injection site reactions and systematic adverse effects. No oral formulations have been clinically tested. Due to unregulated status, preparation and administration carry additional contamination and dosing accuracy risks.
Clinical studies utilized subcutaneous injection, typically in the abdomen or thigh. Injection timing was generally in the morning to align with natural circadian melanocortin rhythms. Lyophilized powder requires reconstitution with bacteriostatic water. Injection sites should be rotated to prevent tissue damage. Research protocols included monitoring for injection site reactions and systematic adverse effects. No oral formulations have been clinically tested. Due to unregulated status, preparation and administration carry additional contamination and dosing accuracy risks.
Clinical Administration Guidelines
Injection Protocol
- •RESEARCH ONLY - subcutaneous injection protocols not approved
- •RESEARCH ONLY - rotate abdomen/thigh sites
- •RESEARCH ONLY - morning injection in studies
- •RESEARCH ONLY - fasting may reduce nausea
Monitoring Schedule
- •CRITICAL: Monitor moles, skin changes, and sexual side effects
- •CRITICAL: Weekly dermatological examination
- •CRITICAL: Liver/kidney function tests
- •STOP IMMEDIATELY if priapism, severe nausea, or new moles develop
Dosage Calculator
Medical Disclaimer
CRITICAL WARNING: Melanotan-2 is NOT approved by the FDA or any major regulatory agency for human use. Health authorities worldwide have issued warnings against its use due to serious safety risks including potential melanoma, priapism, rhabdomyolysis, and systemic toxicity. This information is for educational and research purposes only. Any use requires medical supervision and carries significant legal and health risks. Consult healthcare providers for approved alternatives.